Testing a new antibody with chemo for locally advanced throat cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests nituzumab (a targeted antibody) added to standard induction chemotherapy versus placebo plus chemotherapy. It aims to improve tumor control and safety for people with locally advanced nasopharyngeal (throat) cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent in writing and join voluntarily
- You are age 18 to 70, and your cancer is nasopharyngeal squamous cell cancer confirmed by biopsy
- Your cancer stage is locally advanced (not already spread to distant organs) and the tumor/lymph nodes can be measured
- Your tumor test shows EGFR is positive, and a specified score (Kaplan score) is above 70
- Your blood, liver, and kidney tests are strong enough for study treatment
- You have not had prior treatment with surgery (beyond biopsy) or radiation, and you haven’t had chemo, immunotherapy, or EGFR-targeted therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a PD-1 inhibitor to standard chemotherapy (TPF) before the main treatment can shrink advanced nasopharyngeal cancer that has spread beyond the nasopharynx. It is for people who have not had any prior treatment for their cancer.
This Phase 3 trial compares different chemotherapy drugs given along with radiation therapy for people with locally advanced nasopharyngeal cancer. It aims to find which drug approach works better and is safer for this stage of disease.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This trial tests whether taking the chemo tablet capecitabine after standard chemoradiation can help prevent cancer from coming back, and whether adding an immune therapy (a PD-1 antibody) improves results. It is for people with high-risk nasopharyngeal (throat) cancer whose main treatment has already finished.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
This trial tests whether adding a medicine called TNF to standard chemotherapy and radiation helps people with locally advanced nasopharyngeal cancer. It also compares outcomes between giving TNF and not giving TNF, to see which approach works better and is safe.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.